Delivery Order SPE2DB24D2205-SPE2DB25FEFZC
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) valued at $1,783.60 with a firm fixed price structure. This competitively awarded, non-set-aside contract is a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order is scheduled for...
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $1,946.85 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on September 18, 2025, with completion scheduled for September 19, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $1,100.64. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply transaction under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a $15,814.20 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 26, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,269.13 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,609.67 to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100 count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price delivery order, issued with no set-aside designation, is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's broader contracting...
- The Defense Logistics Agency awarded a delivery order valued at $2,174.23 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on June 2, 2025, with an ultimate completion date of June 3, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyvanse 30 mg capsules (100-count) with a contract value of $2,117.56 and completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEFZCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,437.80 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on August 7, 2025, with completion scheduled for August 8, 2025. This non-competitive, firm fixed-price delivery order represents a single pharmaceutical transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement across military and veteran healthcare systems. The ordering activity reflects the company's role within the DLA Medical Supply Chain, which sources medications and medical supplies to support defense health operations. This delivery order is a child contract under AmerisourceBergen Drug Corp's prime indefinite delivery vehicle (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent contract functions as a comprehensive global pharmaceutical support vehicle enabling the supply of brand-name and generic drugs, vaccines, specialty medications, and related medical commodities across multiple therapeutic domains to support military healthcare programs worldwide. The Vyvanse order exemplifies the routine, competitively-awarded transactional activity flowing from this large-scale IDC, which serves defense customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 8/7/25 |